To some people we may be entering the period of the ‘Fourth Industrial Revolution’ - the Biological Industrial Revolution. Just as in previous industrial revolutions the potential previously promised by coal, mechanisation and electronics has now to be realised by the exploitation of biological potential. This new potential is made available by large scale gene synthesis and expression and understanding the options available for the scale-up and control of novel genetic entities. It seems that in order to start to understand fully how the exploitation of novel biological potential may be realised there needs to be a recognition of the scale and complexity of the task. Novel methodologies in numerical analysis and experimental design as well as in automation and bioprocess engineering need to be employed and coordinated in order to gain commercial traction on synthetic biology. This short talk will seek to identify how techniques of large scale experimental design, scale up and analyses, as well as a novel approach to biological automation are seeking to address just some of the issues surrounding Synthetic Biology and delivering on ‘From Gene to Product’.
Short biography of Mr. Craig JL Gershater:
Craig is a senior scientist and manager with over 40 years’ industrial bioprocess optimisation and biotechnology experience. He has held a variety of senior positions in the pharmaceutical industry, lastly as Head of Fermentation Sciences R&D at SmithKline Beecham prior to becoming the CEO and Principal Consultant with Cambridge Bioprocess Management Ltd in 2000. Among his many transnational clients in recent years he has worked with GSK, as well as a number of SMEs and in academia. He is an expert in the application of statistical methods to experimental design and rapid bioprocess optimisation. He has used these techniques in a wide variety of industrial research and development projects including full scale development of biotechnology projects to GMP/GLP requirements.